Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Cerny

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Analytical and Bioanalytical Chemistry|October 14, 2004
1H high-resolution magic-angle spinning (HR-MAS) NMR analysis of ligand density on resins using a resin internal standardLaura H Lucas, Matthew A Cerny, Yakov M Koen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 20, 2012
Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserinAbu J M Sadeque, Khawja A Usmani, Safet Palamar, et al.
Journal of Medicinal Chemistry|November 28, 2006
Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallizationJason K Yano, Travis T Denton, Matthew A Cerny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 14, 2016
Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate FormationAbu J M Sadeque, Safet Palamar, Khawja A Usmani, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 19, 2014
Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382J Matthew Hutzler, Matthew A Cerny, Young-Sun Yang, et al.
Journal of Medicinal Chemistry|February 26, 2020
Effective Application of Metabolite Profiling in Drug Design and DiscoveryMatthew A Cerny, Amit S Kalgutkar, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2021
Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and HepatocytesElaine Tseng, Heather Eng, Jian Lin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2026
Molnupiravir is not a selective CES2 probe substrate: in vitro evidence for CES1 involvementLuke Roberts, Hannah Moulton, Xiaofeng Wu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 30, 2026
Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitorManoli Vourvahis, Christine C Orozco, David Tess, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2016
Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman PrimatesSteven M Weldon, Matthew A Cerny, Kristina Gueneva-Boucheva, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Analytical and Bioanalytical Chemistry|October 14, 2004
1H high-resolution magic-angle spinning (HR-MAS) NMR analysis of ligand density on resins using a resin internal standardLaura H Lucas, Matthew A Cerny, Yakov M Koen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 20, 2012
Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserinAbu J M Sadeque, Khawja A Usmani, Safet Palamar, et al.
Journal of Medicinal Chemistry|November 28, 2006
Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallizationJason K Yano, Travis T Denton, Matthew A Cerny, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 14, 2016
Identification of Human Sulfotransferases Involved in Lorcaserin N-Sulfamate FormationAbu J M Sadeque, Safet Palamar, Khawja A Usmani, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 19, 2014
Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382J Matthew Hutzler, Matthew A Cerny, Young-Sun Yang, et al.
Journal of Medicinal Chemistry|February 26, 2020
Effective Application of Metabolite Profiling in Drug Design and DiscoveryMatthew A Cerny, Amit S Kalgutkar, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2021
Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and HepatocytesElaine Tseng, Heather Eng, Jian Lin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2026
Molnupiravir is not a selective CES2 probe substrate: in vitro evidence for CES1 involvementLuke Roberts, Hannah Moulton, Xiaofeng Wu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 30, 2026
Human absorption, distribution, metabolism, excretion, and reaction phenotyping of ervogastat (PF-06865571), a diacylglycerol O-acyltransferase 2 inhibitorManoli Vourvahis, Christine C Orozco, David Tess, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2016
Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman PrimatesSteven M Weldon, Matthew A Cerny, Kristina Gueneva-Boucheva, et al.
Pageof 4